Revised Schedule M and Cameras: What Indian Pharma Plants Need

Revised Schedule M does not require CCTV. What it mandates is a documented quality system, validated computerised systems, and data integrity — none of which a camera can deliver. Where a camera genuinely helps a pharma plant is the human layer around GMP: gowning and change-room discipline, who entered a dispensing or production area, line clearance, and turning "we did the SOP" into evidence you can show a WHO-GMP or customer auditor. Anyone selling you cameras as a "Schedule M requirement" is selling a myth.

Last updated: September 2026. Revised Schedule M was notified as G.S.R. 922(E) on 28 December 2023, amending the Drugs Rules, 1945. Its requirements verified against CDSCO/gazette-derived summaries; there is no CCTV clause in the revised Schedule M text as of this date. Confirm the current gazette text before relying on it.

Key points

• Revised Schedule M does not order CCTV. It mandates a Pharmaceutical Quality System (PQS), quality risk management, product quality review, equipment qualification and validation, and — the part vendors twist — computerised systems with data integrity (ALCOA+). Software and validated systems satisfy that, not cameras.
• The deadline is size-staggered. Large manufacturers (turnover above ₹250 crore) were to comply within six months of the 28 December 2023 notification — around 28 June 2024. Small and medium units (turnover at or below ₹250 crore) got a phased extension, with implementation carried to 31 December 2025 for those who filed a plan. From 1 January 2026 it applies across the board, and CDSCO is running risk-based inspections with licence suspension for failures.
• "Computerised monitoring" ≠ cameras. The rule's computerised-system and data-integrity requirements are about your MES, LIMS, batch records, audit trails and access controls in software — not video. A camera cannot make your electronic records ALCOA+ compliant.
• Where a camera earns its place is the human/GMP-discipline layer: gowning and change-room compliance, unauthorised entry into dispensing/production/clean zones, line-clearance evidence, and matching what a log says happened against what a camera saw happen.
• Environmental monitoring needs sensors, not a lens. Particle counts, temperature, humidity, differential pressure and water-system quality come from instruments and a BMS. A camera can, at most, corroborate that doors stayed shut and monitoring rounds were done.
• Vendor "GMP-ready AI" claims are marketing. Test any gowning or zone-entry detection on your own cleanroom under your own light and gowning colours before you trust a number.

Pharma owners in Baddi, Ahmedabad, Hyderabad or Sikkim have all had the same call from a camera vendor this year: "Revised Schedule M is here — you need CCTV to stay compliant." It is not true, and believing it makes you buy the wrong thing for the wrong reason. Let's separate what the rule actually requires from what a camera can honestly do.

What revised Schedule M actually requires (and what it doesn't)

Revised Schedule M is the modernised Good Manufacturing Practices annexe to the Drugs Rules, 1945, notified as G.S.R. 922(E) on 28 December 2023. It pulls Indian GMP substantially closer to WHO-GMP, EU-GMP and USFDA expectations. In broad strokes it mandates:

• A formal Pharmaceutical Quality System (PQS) governing the whole product lifecycle.
• Quality Risk Management (QRM) and Product Quality Review (PQR) — at least annual review of each product.
• Qualification and validation of equipment, utilities and processes.
• Computerised systems with data integrity — every change to recorded data documented, with audit trails, backups and access controls, aligned to ALCOA+ principles. Electronic batch records and computerised-system validation (CSV) sit here.
• Environmental controls — HVAC validation, cleanroom qualification, water-system qualification and ongoing environmental monitoring.
• Self-inspection / quality audits, change control, deviation management and CAPA.
• A pharmacovigilance system to collect and forward adverse-drug-reaction reports.

Note what is not on that list: any requirement to install CCTV or video surveillance. We could not find a camera clause anywhere in the revised Schedule M text, and multiple regulatory summaries confirm there isn't one. So be precise internally: cameras are a GMP-discipline and audit-evidence tool for pharma, not a legal box the rule tells you to tick.

The confusion comes from one phrase — "computerised monitoring" — that vendors deliberately blur. In Schedule M that means validated computerised systems and data integrity in your software (MES, LIMS, SCADA, electronic records), not a monitoring camera watching the floor. A camera does nothing for your ALCOA+ audit trail.

Deadlines by company size

The obligation is real and dated — it just isn't a camera obligation:

If your consultant is quoting these dates as a reason to buy cameras, that is a non-sequitur — the deadlines are for your quality system, not your camera count. For the general factory-CCTV timeline (which does have real 2026 dates), see the India factory CCTV compliance calendar 2026.

Where a camera genuinely helps a pharma plant

Cameras don't satisfy the rule — but they do strengthen the human discipline that GMP and every auditor scrutinises. A ceiling or wall camera sees people and their behaviour around the process. That is exactly where GMP failures and audit observations cluster.

• Gowning and change-room discipline. Bare head vs. covered, gown on vs. off, correct sequence through the change room — a strong, high-value signal, and a recurring WHO-GMP / USFDA observation area.
• Unauthorised entry into dispensing, production or clean zones. Line-crossing and zone rules corroborate who was where, backing your access-control records.
• Line clearance and changeover. Evidence that the previous product and its labels were removed before the next batch started — a classic mix-up risk and a documented-procedure that a camera can show was actually followed.
• Log-vs-reality matching — the real sweet spot. GMP runs on records that assert an activity happened. A camera turns "the log says cleaning was done at 14:00" into "the camera shows cleaning activity at that station at 14:00." That corroboration is what makes an audit trail credible.
• Audit readiness. WHO-GMP, EU-GMP, USFDA and customer/CDMO audits expect control of critical and dispensing areas. A quarter of timestamped gowning and zone-discipline evidence shortens the audit and shrinks the corrective-action list — even though no rule orders the camera.

Frame it to your own team as audit readiness and GMP discipline, never as surveillance-to-punish. Discipline holds far better when the floor understands the camera protects the plant's licence and its customers' business.

Where you need data systems, not cameras

This is the honest other half, and it is where vendors go quiet:

• Data integrity / ALCOA+. This is a software-and-validation problem — audit trails, user-access controls, time stamps, backups in your computerised systems. A camera contributes nothing here.
• Electronic batch records / MES. Records and their integrity come from the system, not a lens.
• Environmental monitoring. Particle counts, temperature, humidity, differential pressure, and water quality come from instruments, sensors and a building-management system. A camera cannot measure a particle count; at most it corroborates that a door stayed shut or a monitoring round was walked.
• Pharmacovigilance / PSUR, PQR, QRM, CAPA. These are quality-system and data processes. No camera involvement.
• Contamination inside the product. Like food, an overhead camera cannot see inside a vial, blister or fill. In-product quality is analytical and lab testing. Cameras sit around that system, watching the people.

The one-line rule: camera-AI is strong on "is the person gowned, and are they where they should be," and on corroborating that a logged activity happened — and blind to data integrity, environmental parameters and what's inside the product.

Requirement-by-requirement: does a camera help?

Read across, not just down — the "what actually satisfies it" column is where the money decision hides.

Anyone marketing cameras as "Schedule M compliance in a box" is overselling. The rule is satisfied by systems and validation; the camera is a discipline-and-evidence layer around GMP, valuable but optional.

What "good" looks like on a pharma floor

• Cover the choke points, not everything: the change-room / gowning sequence, the entry line into each clean or dispensing area, the dispensing booth, and the line-clearance stage — not benches, canteens or rest areas.
• Draw zones deliberately. A gown is mandatory past the cleanroom airlock, noise elsewhere. Wrong zones = an alarm every minute until someone mutes it, and a muted system is worthless at an audit.
• Plan for the environment: cleanroom light, gowning colours (white gown against a white wall is hard), reflective surfaces and airlocks all degrade detection. Pilot the AI under your conditions, not a demo hall's.
• Cameras are not your data-integrity control. Keep the two budgets separate: your Schedule M spend is quality systems, CSV and environmental instrumentation; the camera is a smaller, separate line for GMP discipline and audit evidence.
• Handle worker-privacy law. Identifiable footage of workers is personal data — post a notice and set a retention schedule before you switch anything on. See the worker CCTV notice your factory needs under DPDP and DPDP and worker CCTV in Indian factories.

For the certified-camera and installation-timing questions that do have hard 2026 dates, work through is CCTV mandatory in Indian factories and the factory CCTV compliance checklist. The pharma story here is the same shape as food manufacturing — cameras in food processing plants: hygiene, FSSAI and buyer audits — the sector rule mandates the practice, and the camera evidences it.

FAQ

Does revised Schedule M require CCTV in a pharma plant? No. Revised Schedule M (notified as G.S.R. 922(E) on 28 December 2023) mandates a Pharmaceutical Quality System, equipment qualification and validation, computerised systems with data integrity (ALCOA+) and environmental controls — not cameras. There is no CCTV clause in the rule. Cameras appear in pharma because WHO-GMP, USFDA/EU-GMP and customer audits expect control of critical and dispensing areas — an audit expectation, not a statutory mandate.

Isn't "computerised monitoring" in Schedule M the same as camera monitoring? No, and this is the myth vendors exploit. Schedule M's computerised-system and data-integrity requirements are about validated software — audit trails, access controls, electronic batch records, backups. A camera does nothing for your ALCOA+ audit trail. Those are two different budgets and two different problems.

When does revised Schedule M apply to my plant? Large manufacturers (turnover above ₹250 crore) were to comply within about six months of the December 2023 notification. Small and medium units (turnover at or below ₹250 crore) received a phased extension carrying implementation to 31 December 2025 for those who filed a plan. From 1 January 2026 it applies across the board, with CDSCO running risk-based inspections and suspending licences for failures. Confirm your unit's status with CDSCO / your state drug controller.

Where do cameras actually add value under GMP, then? The human/discipline layer: gowning and change-room compliance, unauthorised entry into dispensing/clean zones, line-clearance evidence, and corroborating that a logged activity (cleaning, changeover) genuinely happened. That corroboration is what makes an audit trail credible — but data integrity, environmental parameters and in-product quality still need systems, sensors and the lab, not a camera.

Related reading: Is CCTV mandatory in Indian factories? · India factory CCTV compliance calendar 2026 · Factory CCTV compliance checklist · Cameras in food processing plants (FSSAI) · Worker CCTV notice under DPDP.

This article explains the general regulatory landscape and is not legal or regulatory-affairs advice. Revised Schedule M obligations, CDSCO enforcement and audit expectations turn on your turnover, your products, your licences and your specific facts, and the rules are being enforced through 2026. Confirm what binds your plant with CDSCO, your state drug controller and a qualified regulatory-affairs advisor before relying on it for a purchase or a compliance decision.